1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

How J&J Scientist Koul Hopes To Reboot R&D At India’s IMTECH

 
• By Anju Ghangurde

Anil Koul, part of the Johnson & Johnson team that discovered and developed TB drug Sirturo, is currently on a sabbatical to head up IMTECH, an Indian R&D institute. Koul shares with Scrip the ups and downs of Sirturo's development journey and outlines what he hopes to achieve at IMTECH.

Anil Koul
J&J's Dr. Anil Koul takes on a new challenge in India

For any top-notch scientist, shifting from a frontline innovator firm to a government R&D institution in an emerging market like India is, as some industry watchers say, akin to moving from Hollywood to local theater. Smaller budgets, technology constraints, scale limitations and inefficiencies are just some of the general variances that you may have to deal with.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 
• By Jessica Merrill

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

 
• By Anju Ghangurde

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy

 
• By Alaric DeArment

The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.

Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs

 
• By Alaric DeArment

The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.